Key takeaways
Emtricitabine-tenofovir disoproxil fumarate (Truvada) and emtricitabine (Emtriva) are both medications used to treat HIV when taken in combination with other HIV medications. They belong to the same drug class, nucleoside reverse transcriptase inhibitors (NRTIs), and work by stopping the virus from making copies of itself. Truvada is a combination medication that includes both emtricitabine and tenofovir disoproxil fumarate, while Emtriva contains only emtricitabine. Truvada is FDA-approved for both the treatment and prevention of HIV (PrEP), whereas Emtriva is only approved for treatment. Truvada is taken as a single tablet once daily, while Emtriva is available as a capsule or oral solution, with dosing based on age and weight for children. Truvada is available as a lower-cost generic, while Emtriva is not. Common side effects of Truvada include nausea, diarrhea, and dizziness, while Emtriva may cause nausea, fatigue, and diarrhea. Both medications require regular lab tests to monitor kidney and liver health, but Truvada has a higher risk of causing bone problems. Additionally, Truvada can interact with certain hepatitis C medications, increasing the risk of side effects.
